Stay current on changes and developments in corporate law with a wide variety of resources and tools.
By Jacob Rund
IPO-bound companies increasingly cite President Donald Trump and his administration as a potential risk to their business.
As of Nov. 19, 43 percent of companies that priced an initial public offering of $1 million or more this year mentioned Trump and his administration’s policies in their prospectuses or supplemental documents, a Bloomberg Law analysis of corporate filings shows. That’s up from 26 percent in 2017, when 59 of 230 IPO companies named the president in their investment pitches.
The uptick could signal that businesses increasingly feel the need to hedge for the uncertainty resulting from the president’s market-moving statements and actions of his administration.
A bulk of the references covered Trump-backed proposals to alter health care policy, as well as his administration’s testy trade relationship with China and other countries. The president’s support of tax reform legislation, which he signed into law last December, and the accompanying accounting changes also appeared in several offering documents.
“It means that more people are paying attention to Donald Trump,” Adam Pritchard, a University of Michigan Law School professor, told Bloomberg Law. “That’s the takeaway. It’s just part of the zeitgeist.”
Most mentions came in the risk factors section — used to outline circumstances or events that could adversely affect business operations — of prospectuses and related filings that are required by the Securities and Exchange Commission before completing an offering. Multiple companies counted more than one of the president’s decisions, or his administration’s activity, as potential risks.
Arco Platform Ltd., a U.S.-listed educational software provider based in Sao Paulo, Bazil, named Trump in its Sept. 27 prospectus filing as a risk to both its share price and the overall Brazilian economy.
“We have no control over and cannot predict the effect of Donald Trump’s administration or policies,” the document said.
Restoration Robotics Inc., in the final version of its prospectus, cited the regulatory risks posed by a Trump executive order that placed new rulemaking requirements on federal agencies aimed at eliminating some existing rules. The company said there could be a negative business impact if the new policies hamper the Food and Drug Administration’s ability to issue guidance and approve companies’ marketing proposals.
Risk disclosures serve as legal protection against lawsuits claiming that omissions or misstatements in offering documents harmed stockholders. They’re “meant to give investors some idea about things that could go wrong,” Pritchard said.
President Barack Obama’s appearances in IPO filings during his first two years in office were less frequent. About 24 percent of 78 companies that priced IPOs of at least $1 million in 2009 — in the midst of the financial crisis — mentioned him in their filings. The number dipped to 14 percent the following year, when just 27 of 197 companies referenced Obama’s policies or his administration’s actions, filings show.
Obama’s mentions may be lower than Trump’s, but companies still likely referenced Obama’s policies frequently in their filings during the late 2000s, Pritchard said.
“I’ll bet if you looked at companies in the medical care business” during Obama’s initial term, “you would find some risks to their business from not knowing what’s going to happen with health care reform,” he said. “They might not have referred to Obama by name, but in substance would it be any different?”
Political factors are frequently included in corporate risk disclosures, although, more often than not, they take the form of company-specific regulatory issues. A pharmaceutical company, for example, may cite the risk of failing to gain government approval of a new drug.
Companies may occasionally mention the risk of a CEO departure. Naming other individuals, even presidents, is otherwise unusual in IPO disclosures. “There’s no requirement to mention an individual or a specific industry competitor,” said Karen Nelson, a Texas Christian University accounting professor who researches periodic filings with the SEC. “I just haven’t seen a lot of individuals named outside of a CEO.”
The increased appearance of Trump in these filings suggests that trend might be shifting.
There can be added pressure when crafting the risk factors in a prospectus than those in a quarterly or annual filing. Companies often face more scrutiny and liability at the time of an IPO.
Citing an individual, while unusual, wouldn’t be “crazy” if a company thought that person was likely to have a regulatory impact on its business, Pritchard said.
The fear of leaving out a risk factor that others are including might also be driving the uptick in mentions of Trump in IPO filings.
There’s “a lot of copying that goes on” among companies crafting their disclosures, Pritchard said. “You’re erring on the side of inclusion, and if your competitors are doing it, you probably are inclined to do it too so you don’t stand out.”
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)